CN101961326A - Application of physcion in preparing medicines for treating depression - Google Patents
Application of physcion in preparing medicines for treating depression Download PDFInfo
- Publication number
- CN101961326A CN101961326A CN 201010524378 CN201010524378A CN101961326A CN 101961326 A CN101961326 A CN 101961326A CN 201010524378 CN201010524378 CN 201010524378 CN 201010524378 A CN201010524378 A CN 201010524378A CN 101961326 A CN101961326 A CN 101961326A
- Authority
- CN
- China
- Prior art keywords
- depression
- group
- medicine
- physcione
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses application of physcion used as an active component in preparing medicines for treating depression. The physcion has the characteristic of little toxicity, and can be used for preparing medicines for preventing or treating various kinds of depression, including endogenous depression, reactive depression, masked depression, secondary depression caused by medicines, climacteric depression or postpartum depression, depression induced by cerebral trauma or cerebrovascular disorder and depressive neurosis as well as diabetes companied by depression and related diseases.
Description
Technical field
The invention belongs to medicine, especially from natural plants, extract the new medicine use of the physcione that obtains, be specifically related to their application in preparation treatment depression product.
Background technology
Physcione (physcion) belongs to anthraquinone analog compound, has another name called Radix Aristolochiae Kaempferi second element, non-this ketone, and molecular formula is C
16H
12O
5, chemical name is 1,8-dihydroxy-3-methoxyl group-6-tectoquinone.It is the most a kind of anthraquinones that distributes, extensively be present in Polygonaceae, pulse family, Labiatae, Compositae, the orchid family and the rosaceous many kind of plant, Recent study is also found also to contain physcione in the Chinese medicines such as Radix Morindae Officinalis, Radix Ampelopsis, Cortex Lycii, Radix Wikstroemae and Rhizoma Cyperi.Physcione mainly is to extract to obtain from the Semen Cassiae of Chinese herbal medicine polygonaceae plant Radix Et Rhizoma Rhei, Rhizoma Polygoni Cuspidati and Radix Polygoni Multiflori and pulse family.In recent years, a large amount of further investigations that the pharmacological mechanism of physcione carries out are found, physcione have many pharmacotoxicological effects as: 26 kinds of antibacterials such as staphylococcus aureus, escherichia coli, bacillus pyocyaneus, streptococcus and dysentery bacterium, Candida albicans, Cryptococcus histolyticus, trichophyton mentagrophytes and Aspergillus fumigatus are all had inhibitory action, rice blast fungus, botrytis cinerea pers and obligate parasite wheat powdery mildew and Fructus Cucumidis sativi white lead are all had tangible activity, simultaneously bacterium of downy mildew of cucumber is also had fungistatic effect significantly; In Salmonella TA1535 test mutation effect is arranged; Stronger to the effect of human body s growth inhibited; MCF-7 has cytotoxic activity to breast cancer cell.Physcione can pass through blood brain barrier simultaneously, has very strong antiinflammatory action, can shorten the hemorrhage and clotting time of animal, alleviates the ischemic pathological lesion, and cerebral ischemia reperfusion injury is had antagonism.Physcione also has protective effect to the rat acute hepatic injury in addition.
Depression is the higher major disease of sickness rate.Depression is the common disease of a kind of psychiatric department, add up according to World Health Organization (WHO), depression has become the world's the 4th big illness, China's the 2nd big disease burden predicts the year two thousand twenty, may become the second largest disease that is only second to coronary heart disease, account for 15% of global disease burden, the sickness rate of lifelong depression is between 6%-8%, and along with the progressively aging of population, the sickness rate of depression in crowd more than 60 years old will be up to 20%-50%.Depressive patients is the high-risk group who commits suiside, and falls ill to convalescence patient, has the danger of committing suiside all the time.The identifying and diagnosing rate of depression is very low, and effectively cure rate is also very low.Existing antidepressant Western medicine mainly is: tricyclic antidepressants (TCAs), selectivity 5-HT reuptake inhibitor (SSRIs), oxidase inhibitor (MAOIs), the toxic and side effects of their equal various degrees, and cost an arm and a leg, thereby the new antidepressants of research and development have important theory and practical significance from Chinese medicine.
Summary of the invention
In view of the above shortcoming of prior art, the objective of the invention is to study one, to make physcione be the medical usage more widely of the medicine of active component, makes its being applied in preparation treatment depression medicine.
The present invention has studied the application of physcione in preparation treatment depression medicine, take the physcione as effective ingredient manufacturing control depression medicine.
The invention provides and contain the purposes of physcione as prevention and treatment depression medicine, it has the little characteristics of toxicity, and degradation under the learning memory of depression secondary is had tangible mitigation.Physcione or be used to prepare with its Pharmaceutical composition of forming as active component etc. depression that prevention or treatment comprise that endogenous depression, reactive depression, masked depression, drug-induced secondary depression, climacteric or postpartum depression, cerebral trauma or apoplexy bring out and depressive neurosis various depressive symptoms medicine application and be used for diabetes and merge depression, and be used to prepare prevention and treat the insecondary learning and memory decline that depression causes, the application in the medicine of symptoms such as anhedonia.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
Below zoopery be to further describe to of the present invention, but and do not mean that any limitation of the invention.Obviously, since the selected laboratory animal pharmacology feasible popularity that has expressed the present invention use should trace back and the animal realm.
Laboratory animal: male kunming mouse, begin to test body weight 18g-30g, purchase medical experiment animal center in Sichuan Province, the quality certification number: SCXK[river] 2008-14, accept 12h illumination/12h dark every day, periodicity of illumination is 8:00-20:00,20 ± 2 ℃ of laboratory temperatures, humidity 60%, animal can absorb standard feed and cleaning water voluntarily, and International Laboratory Animal ethics requirement is observed in zoopery.
Medicine:
Physcione (standard substance) is provided by Kunming section Xiang bio tech ltd, makes the suspendible medicinal liquid with 0.5% shuttle methylated cellulose aqueous solution, and is standby.
Experimental program:
1, behavior despair (behavioural despair, BD) depression model
The BD model comprises forced swimming experiment (Forced Swimming Test, FST) and outstanding tail experiment (Tail Suspension Test, TST), its theoretical basis is: under the stressed condition of forced swimming or outstanding tail, animal via is struggled, and the back appearance is desperate to show, be motionless state, and antidepressant can shorten the dead time of animal.Dead time after the former is draped with animal with dead time, the latter of animal in water is as the index of estimating depressed degree.Because changing almost, the behavioristics of this type of animal pattern can be reversed by now clinical applied most antidepressants, have responsive, easy characteristics, so be usually used in the rapid screening of antidepressants, be the animal model that present antidepressant drug screening is most widely used.But the factor that influences the BD model is more, all may have influence on the accuracy of experimental result as the judgement of the motionless state of animal, the quiet degree of environment and the time of experiment etc.
Experimental technique:
100 random packet of KM mice are the high, medium and low dosage group of normal control group, physcione, amount to 5 groups, every group of 20 animals, and each treated animal dosage regimen is as follows:
⑴ normal control group: distilled water; ⑵ physcione high dose group 200mg/kg.d;
⑶ dosage group 100mg/kg.d in the physcione; ⑷ physcione low dose group 50mg/kg.d (5) prozac group: 5mg/kg.d
Outstanding tail experiment (Tail Suspension Test, TST)
Each treated animal gastric infusion every day 1 time, successive administration 7 days, last day, positive controls was given prozac, behind the administration 30min, mouse tail was fixed with clip apart from the about 2cm of end place, made the mice reversal of the natural order of things in outstanding boot, and its head is about 5cm at the bottom of case.Mice gets started observation after hanging 2min, observes to continue 6min the dead time of mice in this 6min of accumulative total (mice stops to struggle, or tiny limb motion is only arranged) aloft.
The forced swimming experiment (Forced Swimming Test, FST)
After each is organized the mice last and gives relative medicine or distilled water 30min, mouse head is put into the swimming cup of diameter 16cm, depth of water 18cm down, 25 ± 2 ℃ of water temperatures are immediately with the dead time in the stopwatch record mice 6min.
Each group of table 1 to the influence of dead time in the mouse tail suspension experiment and in the forced swimming experiment (
± S)
| Group | n | The outstanding tail dead time (second) | Non-swimming time (second) |
| Matched group | 20 | 141.08±34.89 | 68.15±28.61 |
| The prozac group | 20 | 80.09±28.38 △△ | 34.21±12.28 △△ |
| The high group of big first | 20 | 94.47±26.12 △ | 40.14±49.32 △ |
| Organize in the big first | 20 | 106.71±35.97 △ | 69.93±56.83 |
| The low group of big first | 20 | 123.13±37.63 | 54.13±42.68 |
Annotate: compare with matched group
△P＜0.05,
△ △P＜0.01
From above experimental result as can be known, the high dose group of physcione and middle dosage group have tangible antidepressant effect to the desperate depression model of behavior.
2, to the influence of drug-induced depressive state
Chemical compounds such as reserpine mainly comprise by the symptomes complice that monoamine transmitters in the exhaustion brain brings out animal: body temperature decline, blepharoptosis and movable the inhibition.The generation of these symptoms may reduce monoamine transmitters in the brain with reserpine. 5-hydroxy tryptamine (5-HT) especially, and the result that supervention 5-HT receptor sensitivity changes.The monoamine transmitters system mainly comprises 5-HT system, NE system and dopamine (DA) system, plays an important role in the pathogenesis of depression.5-HT in patients with depression brain and the cerebrospinal fluid, 5-HI-AA, the NE equal size is all low than the normal person.5-HT relates to the adjusting of emotion, sleep, vigilance, memory and appetite etc., and the NE deficiency then can cause spirit sluggish.Monoamine oxidase, MAO (MAO) is that (important inactivator DA) if this enzyme is suppressed, will make monoamine transmitters content increase in the brain to monoamine transmitters for 5-HT, NE, and this has positive effect to improving depression.In 1950's, people are when observing the curative effect of antihypertensive reserpine, and discovery has the patient of 10-15% to take this medicine for a long time approximately can produce depressive symptom.Pharmaceutical research afterwards shows, the basic pharmacological action of reserpine is the monoamine neurotransmitter of exhausting in the teleneuron vesicle, the monoamine hypothesis of depression has been proposed thus. think that it is the depressed mechanism that takes place that the synaptic space monoamine neurotransmitter reduces, and antidepressants reduce and the performance antidepressant effect mediator metabolism by blocking-up monoamine-reuptake or inhibition monoamine oxidase, MAO (MAO).
Experimental technique:
120 random packet of KM mice are normal control group, model group, prozac group, the high, medium and low dosage group of physcione, amount to 6 groups, every group of 20 animals, and each treated animal dosage regimen is as follows:
⑴ normal control group: the oral distilled water of giving; ⑵ physcione high dose group 200mg/kg.d
⑶ dosage group 100mg/kg.d in the physcione; ⑷ physcione low dose group 50mg/kg.d (5) prozac group: 5mg/kg.d (6) model group: reserpine 1mg/kg.d
Each organized mice continuous irrigation stomach distilled water or relative medicine 6 days, and each group is given reserpine 1mg/kg except that normal group, blepharoptosis behind the 60min, behind the 180min body temperature descend, the movable inhibition.30min puts into mice prologue experimental box after mice last administration next day, adapts to 2min, observes level, the vertical movable number of times of the interior mice of 4min subsequently, promptly creep the grid number and the number of times of standing.
Each group of table 2 to mice prologue experiment creep the grid number and the number of times of standing influence (
± S)
| Group | n | The grid number of creeping | The number of times of standing |
| Matched group | 20 | 55.77 ± 13.66 | 18.54 ± 4.70 |
| Model group | 20 | 13.50 ±4.56 △△ | 2.50 ±0.65 △△ |
| The fluoxetine group | 20 | 29.17 ±10.19 ﹡ | 5.42 ±0.30 ﹡ |
| The high group of big first | 20 | 10.08 ±2.96 | 3.69 ±0.11 |
| Organize in the big first | 20 | 16.90 ±3.58 | 6.50 ±0.84 ﹡ |
| The low group of big first | 20 | 16.77 ± 4.14 | 5.08 ± 0.45 ﹡ |
Annotate: compare with matched group
△P＜0.05,
△ △P＜0.01; Compare with model group
﹡P＜0.05.
From above experimental result as can be known, the middle dosage group of physcione and low dose group have tangible antidepressant effect to reserpine induced mice depression model.
3, mice autonomic activities
Experimental technique is the same.
Each organized mice continuous irrigation stomach distilled water or relative medicine 6 days, and each group is given reserpine 1mg/kg except that normal group, blepharoptosis behind the 60min, behind the 180min body temperature descend, the movable inhibition.30min puts into mice autonomic activities instrument after mice last administration next day, the movable number of times in the record 5min.
Each group of table 3 to the influence of mice autonomic activities number of times (
± S)
| Group | n | The autonomic activities number of times |
| Matched group | 20 | 92.77 ± 20.15 |
| Model group | 20 | 59.08 ±14.79 △ |
| The fluoxetine group | 20 | 78.11 ±24.02 |
| The high group of big first | 20 | 63.17 ± 10.31 |
| Organize in the big first | 20 | 73.11 ± 12.38 |
| The low group of big first | 20 | 79.00 ± 13.11 |
Annotate: compare with matched group
△P＜0.05,
△ △P＜0.01; Compare with model group
﹡P＜0.05.
From above experimental result as can be known, the low dose group of physcione can improve mice autonomic activities number of times more significantly.
Claims (3)
1. the application of physcione in preparation treatment depression medicine take the physcione as active component manufacturing control depression medicine.
2. the application according to claim 1, it is characterized in that, the medicine of described control depression at preparation prevention and treatment endogenous depression or/and reactive depression or/and masked depression or/and drug-induced secondary depression or/and climacteric or postpartum depression or/and the depression that cerebral trauma or apoplexy bring out or/and the purposes in the medicine of depressive neurosis.
3. according to claim 1 or 2 described application, it is characterized in that the medicine of described control depression descends or/and the purposes in the anhedonia disease drug at the insecondary learning and memory that preparation prevents and the treatment depression causes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105243783A CN101961326B (en) | 2010-10-29 | 2010-10-29 | Application of physcion in preparing medicines for treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105243783A CN101961326B (en) | 2010-10-29 | 2010-10-29 | Application of physcion in preparing medicines for treating depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101961326A true CN101961326A (en) | 2011-02-02 |
| CN101961326B CN101961326B (en) | 2012-02-01 |
Family
ID=43514504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105243783A Expired - Fee Related CN101961326B (en) | 2010-10-29 | 2010-10-29 | Application of physcion in preparing medicines for treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101961326B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392746A (en) * | 2013-08-26 | 2013-11-20 | 湖南农业大学 | Application of Polygonum multiflorum extract |
| CN105497160A (en) * | 2015-12-29 | 2016-04-20 | 西南交通大学 | Application of prepared rhubarb micro powder in preparing medicine for treating depression |
| CN105582068A (en) * | 2015-12-29 | 2016-05-18 | 西南交通大学 | Application of cooked rhubarb micro-powder in preparation of anti-anxiety drug |
| CN110464730A (en) * | 2019-09-12 | 2019-11-19 | 西南交通大学 | Application and relative medicine of the Physcion -8-O- β-D- glucopyranoside in prevention and treatment depression |
| CN114272231A (en) * | 2022-01-27 | 2022-04-05 | 大连大学 | Application of physcion in medicine for relieving drug-induced liver injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008044848A1 (en) * | 2006-10-10 | 2008-04-17 | Digital Biotech Co., Ltd | A composition comprising an extract of rhei rhizoma or physcion compound isolated therefrom for treating or preventing cognitive dysfunction and the use thereof |
| KR20100009415A (en) * | 2008-07-18 | 2010-01-27 | 경북대학교 산학협력단 | Composition of treatment for alzheimer disease comprising mesenchymal stem cells |
-
2010
- 2010-10-29 CN CN2010105243783A patent/CN101961326B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008044848A1 (en) * | 2006-10-10 | 2008-04-17 | Digital Biotech Co., Ltd | A composition comprising an extract of rhei rhizoma or physcion compound isolated therefrom for treating or preventing cognitive dysfunction and the use thereof |
| KR20100009415A (en) * | 2008-07-18 | 2010-01-27 | 경북대학교 산학협력단 | Composition of treatment for alzheimer disease comprising mesenchymal stem cells |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103392746A (en) * | 2013-08-26 | 2013-11-20 | 湖南农业大学 | Application of Polygonum multiflorum extract |
| CN105497160A (en) * | 2015-12-29 | 2016-04-20 | 西南交通大学 | Application of prepared rhubarb micro powder in preparing medicine for treating depression |
| CN105582068A (en) * | 2015-12-29 | 2016-05-18 | 西南交通大学 | Application of cooked rhubarb micro-powder in preparation of anti-anxiety drug |
| CN110464730A (en) * | 2019-09-12 | 2019-11-19 | 西南交通大学 | Application and relative medicine of the Physcion -8-O- β-D- glucopyranoside in prevention and treatment depression |
| CN114272231A (en) * | 2022-01-27 | 2022-04-05 | 大连大学 | Application of physcion in medicine for relieving drug-induced liver injury |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101961326B (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6343389B2 (en) | Use of a fililine / filigenin composition in the preparation of a drug or health care product for the reduction and / or treatment of viral diseases, and a drug or health care product for the treatment of viral diseases | |
| CN101961326B (en) | Application of physcion in preparing medicines for treating depression | |
| KR101735151B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| Owoyele et al. | Studies on the analgesic, anti-inflammatory and antipyretic effects of Parquetina nigrescens leaf extract | |
| CN101961325B (en) | Application of emodin in preparation of drugs for treating depression | |
| CN101284050B (en) | Corydalis tuber water soluble part medicament and its preparation method and application | |
| CN102526573A (en) | Medicament for treating child cold | |
| CN101856438B (en) | Medicinal composition for treating infant asthma and preparation method and use thereof | |
| CN106456690A (en) | Composition containing piper longum l. extract for preventing, treating, and alleviating urinary disturbances | |
| CN101966193B (en) | Application of 2,3,5,4-tetrahydroxystilbene-2-O-beta-D-glucoside to preparing medicaments for treating depression | |
| CN103881891A (en) | Lipid-reducing vinegar and preparation method thereof | |
| CN105395600A (en) | Application of cyclocarya paliurus extract in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| Mugabo et al. | Effects of hippadine on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN100435817C (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| CN107648346A (en) | Application of the safron based composition in preparing treatment or improving the medicine of depression | |
| CN103191356A (en) | Antibacterial spray and preparation method thereof | |
| CN105919991B (en) | Application of the euparin in preparation medicament for treatment of depression | |
| CN101721437B (en) | Preparation method of medicine composition used for treating chronic pharyngitis | |
| CN105412265A (en) | Ranunculi ternati radix extract and application thereof | |
| CN101513498B (en) | Chinese medicament for treating sexual function obstacle of male | |
| Ahad et al. | Fabrication and evaluation of glimepiride Cordia dichotoma G. Forst fruit mucilage sustained release matrix tablets | |
| CN101502537A (en) | Application of ginkgo episperm dry distillation liquid in preparing medicament for treating or preventing fungal disease | |
| CN105497160A (en) | Application of prepared rhubarb micro powder in preparing medicine for treating depression | |
| CN102579730B (en) | Medicine composition for treating acute or chronic cholecystitis and acute or chronic pancreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120201 Termination date: 20161029 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |